Karyopharm Therapeutics (KPTI)
(Delayed Data from NSDQ)
$0.96 USD
-0.01 (-1.31%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $0.96 0.00 (-0.02%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Karyopharm Therapeutics Inc. [KPTI]
Reports for Purchase
Showing records 121 - 140 ( 386 total )
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
European Commission Approves Nexpovio Plus Dexamethasone for the Treatment of Multiple Myeloma
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
4Q20 Results; Pandemic Impacted 4Q20 Sales, But Additional Indication and European Launch Should Boost Sales in 2021
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Xpovio Receives Approval in Israel for the Treatment of Patients With MM and DLBCL
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Nexpovio (selinexor) in Refractory MM Patients Receives Positive CHMP Opinion
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Biotech Should Keep the Wind at its Back in 2021; Top Healthcare Picks
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Karyopharm Announces Preliminary 4Q20 and FY20 Sales
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Xpovio Approved Three Months Earlier Than Expected for 2L and 3L MM; PT to $49
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
NCCN Adds Three Xpovio Combination Regimens to NCCN Guidelines
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Many Positive ASH Presentations Display the Benefits of Xpovio in Several Indications
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended November 20
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
More Good News for Xpovio in Solid Tumors; Phase 3 SIENDO Study Passes Interim Futility Analysis
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E